Fenbendazole, Ivermectin, and Mebendazole in Colorectal Cancer: A Structured Evidence Mapping Analysis of 79 Published Case Reports and Testimonials

By Editorial Team May 19, 2026

Abstract

Background

Repurposed antiparasitic agents including Ivermectin, Fenbendazole, and Mebendazole have gained substantial public attention as potential adjunctive therapies for colorectal cancer. Online compilations of anecdotal reports have expanded rapidly following social media amplification, celebrity endorsements, and physician-curated testimonial series. (onedaymd.com)

Objective

To systematically reorganize and critically analyze 79 published colorectal cancer case reports and testimonials involving ivermectin-, fenbendazole-, or mebendazole-based regimens, with emphasis on tumour biology, metastatic patterns, regimen heterogeneity, evidence hierarchy, and potential sources of bias.

Methods

A structured qualitative evidence-mapping analysis was conducted using publicly available case reports and testimonials compiled in a widely circulated colorectal cancer review article published by OneDayMD. Cases were stratified by cancer subtype, disease stage, metastatic distribution, therapeutic regimen, treatment context, response category, and evidence quality. Narrative synthesis was used to identify recurring patterns and methodological limitations. (onedaymd.com)

Results

The dataset revealed profound heterogeneity across tumour biology, treatment exposure, and evidentiary quality. “Colorectal cancer” cases included adenocarcinoma, rectal squamous cell carcinoma, appendiceal cancer, neuroendocrine tumours, mucinous/signet-ring variants, and mixed gastrointestinal primaries. Four major therapeutic clusters emerged: ivermectin + fenbendazole, ivermectin + mebendazole, triple-agent regimens, and augmented protocols including cannabidiol oil, modified citrus pectin, methylene blue, or chlorine dioxide. Liver-only metastases demonstrated the most favorable reported responses, whereas peritoneal carcinomatosis and osseous metastases appeared less responsive. Approximately 20 cases reported complete remission or no evidence of disease, while most others described partial radiographic responses or biomarker improvement. However, only one randomized controlled trial and one peer-reviewed case report were identified; the majority consisted of physician-curated testimonials and social media narratives. (onedaymd.com)

Conclusions

The available evidence remains highly anecdotal and vulnerable to survivorship bias, publication bias, exposure misclassification, and confounding from concurrent standard oncologic therapy. Nonetheless, recurring observational patterns—particularly among low-volume metastatic disease and liver-dominant colorectal cancer—may justify future prospective investigation. Current evidence should be interpreted as hypothesis-generating rather than practice-changing.

Keywords: colorectal cancer, ivermectin, fenbendazole, mebendazole, repurposed drugs, drug repurposing, case series, evidence mapping, integrative oncology

Introduction

Colorectal cancer remains one of the leading causes of cancer mortality worldwide, with metastatic disease accounting for the majority of deaths. Despite advances in chemotherapy, immunotherapy, targeted therapy, and surgical techniques, long-term survival in advanced-stage colorectal cancer remains limited for many patients. Consequently, interest in adjunctive and repurposed therapies has grown substantially in recent years.

Among the most discussed repurposed agents are ivermectin, fenbendazole, and mebendazole. Preclinical studies have suggested potential anticancer activity through mechanisms involving:

microtubule disruption,
Wnt/β-catenin pathway modulation,
mitochondrial dysfunction,
cancer stem-cell inhibition,
autophagy induction,
and immune modulation. (onedaymd.com)

Online interest accelerated following viral social media testimonials and high-profile endorsements. In 2025–2026, discussions surrounding ivermectin and fenbendazole increased sharply across podcasts, social media platforms, Substack publications, Reddit communities, and physician-curated testimonial databases. (New York Post)

However, the published anecdotal evidence is highly fragmented. Cases are often presented without standardized grouping, tumour stratification, response criteria, or acknowledgement of confounding variables. This limits interpretability and risks overstating efficacy signals.

The present analysis reorganizes these reports into clinically meaningful subcategories to better characterize:

tumour heterogeneity,
treatment heterogeneity,
metastatic response patterns,
evidence quality,
and major methodological limitations.

Methods

Data Source

Case reports and testimonials were extracted from the colorectal cancer compilation published by OneDayMD colorectal cancer review. (onedaymd.com)

The source included:

physician-curated testimonials,
patient-submitted narratives,
social media reports,
peer-reviewed case reports,
and one randomized clinical trial reference.

Inclusion Criteria

Included cases met at least one of the following:

colorectal adenocarcinoma,
rectal cancer,
appendiceal malignancy,
anal squamous cell carcinoma,
gastrointestinal neuroendocrine tumour,
or metastatic gastrointestinal cancer treated with ivermectin and/or benzimidazole therapy.

Analytical Framework

Cases were reorganized into six principal domains:

Tumour subtype
Therapeutic regimen
Metastatic distribution
Treatment context
Reported outcome category
Evidence hierarchy

Results

1. Tumour Biology Heterogeneity

The dataset revealed that “colorectal cancer” encompassed multiple biologically distinct diseases rather than a unified tumour category.

Identified subtypes included:

conventional colorectal adenocarcinoma,
rectal adenocarcinoma,
appendiceal adenocarcinoma,
anal squamous cell carcinoma,
mucinous carcinoma,
signet-ring carcinoma,
rectal neuroendocrine tumours,
small bowel neuroendocrine tumours,
and dual-primary gastrointestinal cancers.

This distinction is clinically important because:

neuroendocrine tumours may demonstrate indolent natural history,
appendiceal tumours possess unique peritoneal dissemination biology,
squamous cell carcinomas respond differently to radiation and chemotherapy,
and signet-ring cancers typically exhibit aggressive dissemination patterns.

Pooling these diseases together risks substantial biological confounding.

2. Therapeutic Regimen Clusters

Four major therapeutic patterns emerged.

A. Ivermectin + Fenbendazole

The most common regimen involved:

ivermectin,
fenbendazole,
and supportive supplements such as vitamins or CBD oil.

Reported ivermectin dosing ranged from:
0.2 mg/kg/day to 1.5 mg/kg/day.

Fenbendazole dosing ranged from:
222 mg/day to 2,000 mg/day.

B. Ivermectin + Mebendazole

Some patients substituted mebendazole for fenbendazole, frequently citing:

human pharmaceutical availability,
dosing standardization,
or physician preference.

C. Triple-Agent Protocols

A subset used:

ivermectin,
fenbendazole,
and mebendazole simultaneously.

These protocols were frequently associated with highly advanced metastatic disease.

D. Augmented Metabolic Protocols

Several regimens incorporated:

cannabidiol oil,
modified citrus pectin,
methylene blue,
chlorine dioxide,
dietary interventions,
fasting strategies,
or ketogenic diets.

This extensive heterogeneity creates substantial exposure misclassification, making causal inference extremely difficult.

3. Metastatic Distribution Patterns

Liver-Only Metastases

The strongest apparent responses were observed among patients with:

isolated hepatic metastases,
oligometastatic disease,
or low tumour burden.

Several reports described:

dramatic carcinoembryonic antigen reductions,
PET scan normalization,
or complete radiographic disappearance of liver lesions. (onedaymd.com)

Peritoneal Carcinomatosis

Patients with diffuse peritoneal spread generally demonstrated:

slower responses,
partial stabilization,
or mixed outcomes.

This may reflect:

poor drug penetration,
extensive tumour heterogeneity,
or advanced disease burden.

Bone Metastases

Osseous metastases appeared associated with:

lower complete remission rates,
persistent disease activity,
and greater symptom burden.

4. Treatment Context Stratification

Three distinct treatment contexts emerged.

Adjunctive Therapy

Many patients received ivermectin or benzimidazoles concurrently with:

FOLFOX,
FOLFIRI,
radiation therapy,
surgery,
immunotherapy,
or liver-directed interventions.

These cases cannot establish independent drug efficacy.

Maintenance/Minimal Residual Disease

Some patients initiated repurposed drugs:

after surgery,
after chemotherapy response,
or following tumour debulking.

These cases may represent maintenance strategies rather than active tumour eradication.

Salvage Therapy

The most biologically informative cases involved:

refractory metastatic disease,
failed chemotherapy,
or limited conventional treatment options.

However, these reports were also the most anecdotal and uncontrolled.

5. Outcome Categorization

Complete Remission / No Evidence of Disease

Approximately 20 cases reported:

complete remission,
PET normalization,
or no evidence of disease.

These responses occurred disproportionately in:

Stage III disease,
oligometastatic disease,
and liver-dominant metastases.

Major Partial Responses

Roughly 30 cases described:

substantial tumour shrinkage,
marked CEA decline,
or major PET response.

Mixed or Modest Responses

Approximately 10 cases showed:

temporary stabilization,
modest regression,
or partial biomarker improvement.

Quality-of-Life Benefit

A smaller number reported:

symptomatic improvement,
improved energy,
or reduced pain despite persistent disease.

Non-Responders

Importantly, the dataset underrepresented non-responders. Some social media discussions explicitly acknowledged treatment failures and persistent Stage IV disease. (Reddit)

This strongly suggests survivorship and publication bias.

6. Evidence Hierarchy

The evidence quality varied dramatically.

Randomized Controlled Evidence

Only one randomized clinical study involving mebendazole was identified within the compilation. (onedaymd.com)

Peer-Reviewed Case Reports

A limited number of peer-reviewed oncology case reports were present.

Physician-Curated Testimonials

A substantial proportion of reports originated from social media posts curated by William Makis. (onedaymd.com)

Patient and Family Testimonials

Additional cases consisted of:

anonymous social media comments,
family narratives,
or self-reported imaging interpretations. (Reddit)

This hierarchy is crucial because testimonial aggregation can visually exaggerate efficacy despite low evidentiary reliability.

Discussion

Survivorship-Enriched Observational Dataset

The compilation likely represents a responder-enriched observational cohort.

Patients most likely to appear online include:

unusually motivated survivors,
integrative medicine advocates,
and individuals experiencing favorable outcomes.

Rapid progressors and non-responders are probably underreported.

This creates strong survivorship and publication bias.

Biological Plausibility

Preclinical literature provides some mechanistic rationale for further investigation.

Potential mechanisms include:

tubulin inhibition,
mitochondrial disruption,
inhibition of Wnt/β-catenin signaling,
autophagy modulation,
and cancer stem-cell suppression. (onedaymd.com)

However, many experimental effects occur at concentrations potentially difficult to achieve safely in humans. (New York Post)

Confounding From Standard Therapy

A major limitation is concurrent conventional treatment.

Many “success stories” also involved:

aggressive chemotherapy,
surgery,
radiation,
immunotherapy,
or ablation.

Thus, observed responses may reflect:

standard treatment efficacy,
multimodal synergy,
selection bias,
or natural disease variability.

Neuroendocrine Tumour Inflation Bias

Neuroendocrine tumours may disproportionately inflate perceived efficacy because:

they often progress slowly,
can remain stable for prolonged periods,
and may respond differently from adenocarcinoma.

Future analyses should stratify or exclude NETs.

Social Media Amplification

Interest in ivermectin and fenbendazole increased substantially following viral podcast discussions and online promotion. (New York Post)

This amplification may influence:

patient expectations,
testimonial reporting rates,
and public interpretation of anecdotal evidence.

Limitations

Major limitations include:

absence of standardized response criteria,
inconsistent imaging verification,
lack of pathology review,
heterogeneous dosing,
incomplete follow-up,
survivorship bias,
publication bias,
and absence of matched controls.

The observational nature of the dataset precludes causal inference.

Future Directions

Future research priorities include:

prospective observational registries,
pharmacokinetic studies,
tumour subtype stratification,
biomarker-guided patient selection,
and randomized controlled trials evaluating adjunctive use alongside standard therapy.

Special focus should be placed on:

liver-dominant oligometastatic disease,
maintenance settings,
and molecularly defined colorectal cancer subtypes.

Conclusion

This structured evidence-mapping analysis demonstrates that publicly reported ivermectin-, fenbendazole-, and mebendazole-based colorectal cancer cases are far more heterogeneous than commonly presented online.

Recurring observational patterns—particularly among low-volume metastatic disease and liver-dominant colorectal cancer—may warrant future scientific investigation. However, substantial methodological limitations prevent definitive conclusions regarding efficacy.

At present, the evidence should be interpreted primarily as:

hypothesis-generating,
exploratory,
and highly observational,

rather than evidence sufficient to support clinical recommendations or replacement of standard oncologic care. (onedaymd.com)